Back to top
more

FibroGen (FGEN)

(Delayed Data from NSDQ)

$1.04 USD

1.04
653,315

+0.02 (1.96%)

Updated Apr 26, 2024 04:00 PM ET

After-Market: $1.04 0.00 (0.00%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value D Growth B Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 36% (91 out of 252)

Industry: Medical - Drugs

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Alaunos (TCRT) to Report Q4 Earnings: What's in the Cards?

by Zacks Equity Research

Alaunos Therapeutics (TCRT) is expected to provide an update on its pipeline candidates, Library TCR-T cell therapy and mbIL-15 TCR-T cell therapy, in its fourth-quarter earnings.

FibroGen (FGEN) Reports Q4 Loss, Tops Revenue Estimates

by Zacks Equity Research

FibroGen (FGEN) delivered earnings and revenue surprises of 26.32% and 43.89%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Should You Buy FibroGen (FGEN) Ahead of Earnings?

by Zacks Equity Research

FibroGen (FGEN) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Ekta Bagri headshot

4 Drug, Biotech Stocks Poised to Beat Q4 Earnings Estimates

by Ekta Bagri

We look at a few drug/biotech companies, TBPH, FGEN, AUPH, CYTK, which are poised to beat on earnings in the fourth quarter.

Analysts Estimate ImmunoGen (IMGN) to Report a Decline in Earnings: What to Look Out for

by Zacks Equity Research

ImmunoGen (IMGN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

FibroGen (FGEN) Expected to Beat Earnings Estimates: What to Know Ahead of Q4 Release

by Zacks Equity Research

FibroGen (FGEN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Ardelyx Inc. (ARDX) to Report Q4 Earnings: What's in Store?

by Zacks Equity Research

Ardelyx (ARDX) is expected to report better-than-expected sales growth of its only marketed product, Ibsrela (tenapanor) and provide an update on the NDA resubmission timeline for Xphozah, tenapanor.

Zoetis (ZTS) to Report Q4 Earnings: What's in the Cards?

by Zacks Equity Research

Higher sales of Zoetis' (ZTS) key drugs like Apoquel, Cytopoint, Simparica Trio, Librela and Solensia are expected to have driven sales, partially offset by lower sales of livestock, cattle, poultry and swine products.

GSK's Daprodustat Drug for Anemia Due to CKD Gets FDA Nod

by Zacks Equity Research

GSK announces the FDA approval of daprodustat for the treatment of anemia due to chronic kidney disease (CKD) in adults on dialysis for at least four months.

FibroGen (FGEN) Reports Q3 Loss, Misses Revenue Estimates

by Zacks Equity Research

FibroGen (FGEN) delivered earnings and revenue surprises of -18.07% and 53.74%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Earnings Preview: FibroGen (FGEN) Q3 Earnings Expected to Decline

by Zacks Equity Research

FibroGen (FGEN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

FibroGen (FGEN) Reports Q2 Loss, Misses Revenue Estimates

by Zacks Equity Research

FibroGen (FGEN) delivered earnings and revenue surprises of 17.02% and 18.57%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

FibroGen (FGEN) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

FibroGen (FGEN) delivered earnings and revenue surprises of 19.05% and 120.72%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

ImmunoGen (IMGN) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

ImmunoGen (IMGN) delivered earnings and revenue surprises of 52.38% and 56.39%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

ChemoCentryx (CCXI) Reports Q1 Loss, Misses Revenue Estimates

by Zacks Equity Research

ChemoCentryx (CCXI) delivered earnings and revenue surprises of -83.33% and 78.77%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

FibroGen (FGEN) Expected to Beat Earnings Estimates: Should You Buy?

by Zacks Equity Research

FibroGen (FGEN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Molina Healthcare (MOH) Q1 Earnings Beat on Higher Premiums

by Zacks Equity Research

Molina Healthcare (MOH) boosts premium and bottom-line guidance for 2022, reflecting improving business.

Humana (HUM) Q1 Earnings Beat on Solid Healthcare Services

by Zacks Equity Research

Humana (HUM) still has $2 billion remaining under its share repurchase authorization.

FibroGen (FGEN) Reports Q4 Loss, Lags Revenue Estimates

by Zacks Equity Research

FibroGen (FGEN) delivered earnings and revenue surprises of -113.24% and 62.59%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Aclaris Therapeutics (ACRS) Reports Q4 Loss, Misses Revenue Estimates

by Zacks Equity Research

Aclaris (ACRS) delivered earnings and revenue surprises of -2.78% and 16.98%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Analysts Estimate FibroGen (FGEN) to Report a Decline in Earnings: What to Look Out for

by Zacks Equity Research

FibroGen (FGEN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

FibroGen (FGEN) Q3 Earnings and Revenues Surpass Estimates

by Zacks Equity Research

FibroGen (FGEN) delivered earnings and revenue surprises of 500.00% and 15.25%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

What's in Store for Perrigo (PRGO) This Earnings Season?

by Zacks Equity Research

Perrigo's (PRGO) new products as well as products added through acquisitions are expected to have aided the company's top line in the soon-to-be-reported quarter.

FibroGen (FGEN) Expected to Beat Earnings Estimates: Should You Buy?

by Zacks Equity Research

FibroGen (FGEN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Organogenesis (ORGO) to Post Q3 Earnings: What's in Store?

by Zacks Equity Research

On Organogenesis' (ORGO) upcoming third-quarter earnings call, investor focus is likely to be on the sales performance of its two segments - advanced wound care, and surgical & sports medicine.